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Extracellular adenosine concentrations are regulated by a panel of membrane
transporters which, in most cases, mediate its uptake into cells. Adenosine
transporters belong to two gene families encoding Equilibrative and Concentrative
Nucleoside Transporter proteins (ENTs and CNTs, respectively). The lack of appropriate
pharmacological tools targeting every transporter subtype has introduced some bias on
the current knowledge of the role of these transporters in modulating adenosine levels.
In this regard, ENT1, for which pharmacology is relatively well-developed, has often
been identified as a major player in purinergic signaling. Nevertheless, other transporters
such as CNT2 and CNT3 can also contribute to purinergic modulation based on
their high affinity for adenosine and concentrative capacity. Moreover, both transporter
proteins have also been shown to be under purinergic regulation via P1 receptors in
different cell types, which further supports its relevance in purinergic signaling. Thus,
several transporter proteins regulate extracellular adenosine levels. Moreover, CNT and
ENT proteins are differentially expressed in tissues but also in particular cell types.
Accordingly, transporter-mediated fine tuning of adenosine levels is cell and tissue
specific. Future developments focusing on CNT pharmacology are needed to unveil
transporter subtype-specific events.
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INTRODUCTION
Oscillation of extracellular adenosine levels is physiologically relevant because this nucleoside
is the agonist of four P1 receptors known to modulate many biological functions (Fredholm
et al., 2011; Burnstock, 2017). Indeed, adenosine concentrations in the extracellular milieu are
determined by the balance between its appearance and its removal. In most cases adenosine
appearance is the result of the sequential metabolic action of various ecto-nucleotidases on
nucleotide precursors, ATP being the first nucleotide in this cascade (Dos Santos-Rodrigues
et al., 2014; Nguyen et al., 2015; Pastor-Anglada et al., 2018). However, in particular cell types,
there is experimental evidence supporting the possibility of adenosine also being released from
cells (Almeida et al., 2003). Extracellular adenosine disposal is similarly mediated by either
metabolism, Adenosine Deaminase (ADA) being the enzyme responsible for its conversion into
inosine, or by its uptake into cells, where it is likely to be metabolized and trapped as AMP after
being phosphorylated by Adenosine Kinase (ADK). The relative contribution of each particular
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mechanism to the oscillations of adenosine levels may be cell-
specific and dependent upon the tissue microenvironment, but
is not well-known, although some attempts to address this issue
have been done (Nguyen et al., 2015). In any case, adenosine
removal from the extracellular milieu is likely to play a major role
in regulating adenosine concentrations.
Adenosine cannot freely permeate biological membranes
and its transport across them occurs via selected adenosine
transporter proteins. Accordingly, transport processes are
key modulators of extracellular adenosine disposal. In this
contribution, we plan to provide an updated and critical view on
the particular transporter subtypes likely to mediate adenosine
transport. Evidence supporting the link between transport
processes and purinergic signaling will be also discussed.
ADENOSINE TRANSPORT
MECHANISMS
All adenosine transporters identified so far belong to the SoLute
Carrier (SLC) superfamily, in particular, to gene families SLC28
and SLC29 (Young et al., 2013; Young, 2016; Pastor-Anglada
et al., 2018). SLC28 genes encode three transporter subtypes
known as human Concentrative Nucleoside Transporters 1, 2,
and 3 (hCNT1, hCNT2, and hCNT3). The SLC29 family has
four members, thereby resulting in four transporter subtypes,
known as human Equilibrative Nucleoside Transporters 1, 2,
3, and 4 (hENT1, hENT2, hENT3, and hENT4). Evidence for
additional transporter subtypes, generated by mRNA splicing has
been provided for hCNT3 and hENT2, in both cases leading to
shorter proteins than their corresponding wild type transporters.
Nevertheless, in all cases these small variants appear to be
localized in intracellular compartments (Errasti-Murugarren
et al., 2009; Grañé-Boladeras et al., 2016) and are unlikely to
play any significant role in purinergic signaling. Nevertheless,
it has been shown that hENT2 splice variants can regulate wild
type hENT2 abundance and function at the plasma membrane
(Grañé-Boladeras et al., 2016).
The type of translocation processes implicated in adenosine
transport (i.e., “concentrative” versus “equilibrative”) and the
affinity binding of adenosine to its transporter proteins are key
determinants of adenosine transport efficacy.
hCNTs are obligatory inward transporters which take
advantage of the sodium gradient to accumulate nucleosides
in the cells. Nucleosides and sodium are co-transported with
translocation stoichiometry 1:1 (hCNT1 and hCNT2) and 1:2
(hCNT3). Indeed, those CNT proteins showing the ability
to transport adenosine are excellent candidates to promote
adenosine disposal from the extracellular milieu due to their
concentrative capacity. hENTs are potentially bidirectional,
vectorial transport being determined by the nucleoside
concentration gradient across the membrane. Nevertheless,
it is probable that in some circumstances, functional coupling of
adenosine influx with its intracellular phosphorylation by ADK
enables cells to trap this nucleoside as AMP thereby building
up a transmembrane adenosine gradient which will favor
unidirectional import of adenosine. It is not known whether
adenosine release via these transporters can be explained by
some sort of inefficient, not necessarily uncontrolled coupling
between metabolism and transport.
As introduced above, affinity is also a critical parameter
when discussing the adenosine transport capacity of each
nucleoside transporter subtype. Reported physiological
adenosine concentrations are very low, often below 1 µM
(Fenton and Dobson, 1992; Espinoza et al., 2011; Rose et al.,
2011; Westermeier et al., 2011), although under certain
conditions, such as hypoxia or in tumor microenvironments
where ATP levels can increase considerably, adenosine can also
accumulate above normal physiological concentrations (Blay
et al., 1997) reviewed in de Andrade Mello et al. (2017) and Di
Virgilio and Adinolfi (2017). As shown in Table 1, apparent Km
values for adenosine vary among transporter subtypes, although
some intrinsic variability is observed for the same transporter
subtype, probably as a result of the experimental set used to
calculate this parameter.
Adenosine transport can be determined either by influx
measurements of its radiolabeled form or, at least for CNT-
type transporters, by electrophysiological means. In order to get
accurate determinations of kinetic parameters it is important to
overexpress a particular subtype on a nucleoside-transport null
background, which indeed is very rare, although two mammalian
non-commercial cell lines lacking CNT- and ENT-related activity
had been engineered for this purpose (Mackey et al., 1998; Ward
et al., 2000). On the other hand, determination of adenosine
uptake kinetic constants of endogenous transporters is a big
challenge. In general trends, most cell lines do not retain hCNT-
related activity, because hCNT expression is highly dependent
upon cell differentiation. Moreover, kinetic determinations in
primary cells are not easy either because they co-express several
transporter subtypes showing overlapping substrate selectivity.
Nucleoside uptake by each particular nucleoside transporter
subtype cannot be determined directly. This is a limitation likely
to result in experimental variability. CNT-mediated transport is
Na-dependent, but uptake determinations in saturating sodium
concentrations (normally 120 mM NaCl) incorporate CNT-
and ENT-related transport as well a variable (often small)
residual component likely to be associated with non-specific
binding, to which even the support where the cells grow on
can contribute to. Thus, uptake measurementsin the absence of
sodium are required, being this cation often replaced by choline
(120 mM Choline Cl). CNT-type activity can be calculated
by subtracting uptake rates measured in the absence of Na
from the total uptake activity measured in a Na-containing
medium. Needless to say, uptake rates should be measured
in initial velocity conditions for proper calculation of kinetic
constants. This can be experimentally challenging, particularly
when transporters are overexpressed. Under these conditions
substrate uptake can be very fast and short uptake time points
might be needed (seconds). As mentioned above, it is not correct
to assume that endogenous ENT-type proteins are responsible
for all apparent uptake activity measured in the absence of
sodium. This means in practice that direct measurements
of ENT-related activity cannot be performed either. Thus,
ENTs must be pharmacologically inhibited to figure out their
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TABLE 1 | Affinity constants of human adenosine transporters.
Gene name
protein
Experimental model Type of assay Af. ct. (µM) Reference
SLC29A1
ENT1
Human Erythroleukemia K562 cells.
Endogenous transporters.
Human Umbilical Vein Endothelial Cells (HUVEC).
Endogenous transporters.
Placental microvascular endothelial cells. Endogenous
transporters.
Heterologous expression in PK15NTD (Nucleoside
Transporter Deficient) cells.
Adenosine influx
Adenosine influx
Adenosine influx
Adenosine influx
75
32
53
59
61
82
40
Boleti et al., 1997
Celis et al., 2017
Casanello et al., 2005
Muñoz et al., 2006
Salomón et al., 2012
Escudero et al., 2008
Ward et al., 2000
SLC29A2
ENT2
Human Umbilical Vein Endothelial Cells (HUVEC).
Endogenous transporters.
Placental microvascular endothelial cells. Endogenous
transporters.
Heterologous expression in PK15NTD (Nucleoside
Transporter Deficient) cells.
Adenosine influx
Adenosine influx
Adenosine influx
49
102
77
98
140
Celis et al., 2017
Muñoz et al., 2006
Salomón et al., 2012
Escudero et al., 2008
Ward et al., 2000
SLC29A3
ENT3
hENT3AA, mutated to reach the plasma membrane in
Xenopus laevis oocytes.
136hENT3, deleted to reach the plasma membrane in
Xenopus laevis oocytes.
Adenosine influx pH 5.5
Adenosine influx pH 5.5
1860
1620
1800
Baldwin et al., 2005
Rahman et al., 2017
Kang et al., 2010
SLC29A4
ENT4
Expression in Xenopus laevis oocytes. Adenosine influx pH 5.5 780 Barnes et al., 2006
SLC28A2
CNT2
Expression in Xenopus laevis oocytes. Adenosine influx
Adenosine influx
Electrophysiology
Electrophysiology
8
6
18
23
Yao et al., 1996
Che et al., 1995
Larráyoz et al., 2006
Li et al., 2001
SLC28A3
CNT3
Expression in Xenopus laevis oocytes
Heterologous expression in yeast
Heterologous expression in HeLa cells
Adenosine influx
Electrophysiology
Adenosine influx
Adenosine influx
15
18
2.2
2.4
Ritzel et al., 2001
Gorraitz et al., 2010
Damaraju et al., 2005
Errasti-Murugarren et al., 2008
Interaction of nucleoside transporters with adenosine has been addressed either by determining the influx of radiolabeled adenosine into cells or, for hCNTs, by monitoring
adenosine-induced Na+currents in Xenopus laevis oocytes expressing a particular CNT subtype protein. Apparent affinity constants (Af. ct.) are all given in µM for a better
comparison among all NT subtypes. Endogenous transporters refer to kinetic determinations performed using cell lines which express hENT1 and hENT2 endogenously,
being the contribution of each subtype calculated by selectively inhibiting either hENT1 alone or both hENTs, as explained in the text. Adenosine uptake by hENT3 and
hENT4 can only be measured at acidic pH. Kinetic determinations using the intracellular transporter hENT3 can only be performed if the wild type protein is modified
in a way that sorting signals are blocked, thereby allowing the protein to reach the plasma membrane and determine function. Whether these relatively small structural
alterations can significantly impact on adenosine affinity is not known. hCNT1 is not included in the table because, as explained in the text, even though some adenosine
affinity constants have been reported, its translocation efficacy is extremely poor and we think it cannot be considered an adenosine transporter in a physiological context.
contribution to the remaining transport activity measured in
sodium-free medium. Indeed, both plasma membrane ENTs
(ENT1 and ENT2) can be simultaneously blocked by µM
concentrations of dipyridamole and dilazep, whereas ENT1 can
be selectively inhibited by nM concentrations of the nucleoside
analog NBMPR (Young et al., 2013; Young, 2016; Pastor-Anglada
et al., 2018). Accordingly, ENT1 activity corresponds to the
NBMPR-sensitive component whereas ENT2 contribution to
nucleoside uptake can be calculated by subtracting the ENT1
activity from the dipyridamole-sensitive component (ENT1 and
ENT2 working simultaneously). At this moment, the reader
can easily understand to what extent accurate measurements of
endogenous nucleoside transport activity can be challenging in
primary cells co-expressing all types of transporter proteins.
As introduced above, electrophysiology might be suitable
for accurate kinetic measurements taking advantage of the fact
that hCNT proteins are electrogenic when they translocate
nucleosides and sodium. The two-electrode voltage clamp
technique has been broadly used in transporter biology for
this purpose (Lostao et al., 2000; Larráyoz et al., 2004;
Smith et al., 2004; Slugoski et al., 2008; Gorraitz et al., 2010).
The cRNA coding for a specific transporters is injected in
Xenopus laevis oocytes and, in normal conditions, transporter
function can be assessed after 2 days. Oocytes are clamped and
inward sodium currents triggered by the addition of a particular
hCNT substrate are recorded. Indeed, the intensity of the
applied current to compensate for the transient depolarization
associated with sodium influx, reflects transport activity. In
this particular set up, initial velocity conditions can be easily
achieved, endogenous activity is not interfering and currents may
be a more direct way of measuring hCNT transport function
than when using radiolabeled adenosine influx determinations.
However, the oocyte membrane might show physicochemical
properties different from mammalian plasma membranes.
To what extent the membrane environment of a particular
nucleoside transporter determines function and, eventually,
substrate specificity is not really well-known. In this regard, when
studying a novel polymorphic hCNT3 variant identified in our
laboratory several years ago (Errasti-Murugarren et al., 2008), we
observed that hCNT3 can indeed be found in different membrane
microdomains, hCNT3 proteins located in lipid rafts being more
active than the ones off rafts (Errasti-Murugarren et al., 2010).
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There are many experimental issues which are likely to
affect hCNT-related activity measurements and this may explain
published variability in substrate specificity (adenosine affinity
constants). Despite all these experimental issues, in general terms,
it seems that the transporter proteins showing the highest affinity
for adenosine are hCNTs, in particular, hCNT2 and hCNT3.
In our hands, apparent Km values for adenosine in HEK293
cells expressing hCNT3 are the lowest reported so far among
all nucleoside transporter proteins, 2.4 µM. Nevertheless, what
makes hCNT3 an excellent candidate to modulate extracellular
adenosine levels is the fact that it shows a huge capacity
to concentrate nucleosides inside cells, because of its unique
stoichiometry. Nevertheless, as will be discussed below, hCNT3
is not ubiquitously expressed, meaning that in some particular
cell types hCNT2 would be the one to do the job.
The role of hCNT1 in adenosine regulation requires a more
detailed explanation because there has been an argument in
the past about whether or not this protein is an adenosine
transporter. Apparent Km values for adenosine have been
calculated for rCNT1 when it was expressed in oocytes and
transport assays were performed using radiolabeled nucleosides
(Yao et al., 1996). In this set up, an apparent Km of 26 µM
was reported and discussed to be similar to the one calculated
for uridine (37 µM) (Huang et al., 1994). Nevertheless, under
these conditions the Vmax for uridine was 300 fold higher
than the one calculated for adenosine (Yao et al., 1996).
The same laboratory reported very low, almost negligible,
substrate-induced Na-inward currents when using saturating
concentrations of adenosine (100 µM) in oocytes expressing
the human CNT1 ortholog (Smith et al., 2004). In our
hands currents were undetectable using the same experimental
approach (Larráyoz et al., 2004). In summary, we believe hCNT1
cannot be considered an adenosine transporter protein. However,
we generated some evidence suggesting the possibility that
adenosine can instead bind to the transporter protein without
being translocated. Evidence for adenosine binding is quite
consistent. Most sodium-coupled transporters, among them
hCNTs, show some sodium leakage in the absence of the co-
substrate (a nucleoside in our case). Leakage can be similarly
measured as a current and is dependent upon membrane
potential. Adenosine was shown to block what are called pre-
steady state and steady state currents of the transporter protein
associated with sodium-leakage (Larráyoz et al., 2004). This can
be understood as the consequence of adenosine binding to the
transporter protein. The physiological relevance of this event is
not known.
Regarding ENT proteins, most available literature points to
ENT1 and ENT2 as major players in the regulation of adenosine
levels. Although apparent Km values are definitely higher (even
much higher for hENT2) than the ones reported for hCNT2
and hCNT3, efficient coupling with adenosine phosphorylation
would contribute to generate a huge transmembrane adenosine
gradient which thermodynamically would favor influx via these
transporter proteins. As discussed below, ENT1 is by far the
most studied member within the SLC29 gene family and different
laboratories have provided consistent evidence supporting a role
for this particular subtype in adenosine signaling. ENT3 is mostly
localized in intracellular compartments (probably mitochondria
and lysosomes) but, in any case, its affinity for adenosine seems to
be low enough as to preclude any role for this transporter protein
in adenosine regulation (Baldwin et al., 2005; Kang et al., 2010;
Hsu et al., 2012; Rahman et al., 2017).
Similarly to CNT1, ENT4 also requires some detailed
explanations, because its role in adenosine signaling is still
on debate. ENT4 is evolutionarily distant from the other
three members of the family (Young et al., 2013) and, when
cloned and functionally expressed it was reported to show
poor affinity for nucleosides, whereas it could translocate
monoamine neurotransmitters such as dopamine and serotonin
(Engel et al., 2004). In fact the laboratory that generated
all this information claimed ENT4 to be renamed as PMAT,
from Plasma Membrane Amine Transporter. Interestingly,
ENT4/PMAT shows functional similarity with organic cation
transporters (OCTs), which means that this protein can act
as a polyspecific OCT as the SLC22 gene members encoding
for hOCT1, 2, and 3. Some common substrate structural
determinants between nucleoside transporters and OCTs can be
hypothesized. Indeed the three hOCT proteins can efficiently
translocate the antiviral nucleoside analog lamivudine. Moreover,
they can also interact with several other nucleoside-based
antiviral drugs such as zidovudine, abacavir, and others (Minuesa
et al., 2009). Nevertheless, none of the OCT proteins can
transport natural nucleosides. The possibility of ENT4 playing
a role in adenosine transport was raised by Barnes et al. (2006)
several years ago. These authors demonstrated that serotonin
transport via ENT4 was not pH-dependent, whereas adenosine
transport was. Apparent Km values for adenosine at acidic pH
(5.5) were in the high micromolar range but still were considered
to be compatible with ENT4 being an adenosine transporter
protein in physiological conditions associated with acidosis.
In summary, we have briefly dissected and discussed the
basic biochemical principles and events governing adenosine
transport into cells, by highlighting which are the best
transporter candidates to regulate extracellular adenosine levels,
and therefore, adenosine-mediated purinergic signaling.
ADENOSINE TRANSPORTERS AND
PURINERGIC SIGNALING
Once the plasma membrane transporters likely to be implicated
in the regulation of adenosine levels have been identified, we will
discuss what is the physiological evidence supporting a functional
link between a particular transporter subtype and purinergic
regulation.
Several experimental approaches have been used in this
regard. NT transporter pharmacology is still poorly developed
and no subtype-specific inhibitors are available for CNT proteins,
although this is not the case for ENTs. Indeed, high-affinity
inhibition of ENT1 by NMBPR has proven very helpful. In fact,
the determination of NMBPR-specific binding sites has been
used by different authors to quantify ENT1 expression at the
plasma membrane, even long before ENT1 was identified at the
molecular level (Pickard et al., 1973; Dahlig-Harley et al., 1981;
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Marangos et al., 1982). Besides the pharmacological approach,
functional genomics is also available for ENT1, since Choi
colleagues reported the first NT-subtype knock out mouse model
(Choi et al., 2004; Oliveros et al., 2017). Probably because of
these circumstances, we can say that ENT1 is the most studied
transporter among the two families (SLC28 and SLC29), with
plenty of literature showing a link between ENT1 function and
purinergic regulation. Another experimental approach suitable
for the analysis of adenosine transporters as players in the
purinome, comes from the evidence that selected NT subtypes
(including ENT1) are under purinergic control. This means that
their function is regulated by P1 (but probably also by P2)
type receptors. In the classical set up of purinome function one
would envisage NT proteins being stimulated by adenosine acting
on P1 receptors, thereby promoting extracellular adenosine
removal and ending the purinergic signaling. Moreover, changes
in the expression of particular NT subtypes in physiological
and pathophysiological conditions known to be associated with
increased adenosine levels, further support the role particular NT
proteins might play in purinergic regulation.
ENT Proteins
ENT1 expression in the rat and human brain has been mapped
by different means (i.e., NBMPR binding, mRNA in situ
hybridization and others). ENT1 shows broad cellular and
regional distribution and its role in adenosine signaling is
relatively well-understood (Parkinson et al., 2011). Adenosine is
known to be neuroprotective in various pathological conditions
such as stroke (Cunha, 2016). This is the reason why physiological
mechanisms governing adenosine extracellular levels have been
comprehensively studied. A probable dual role of ENT proteins
either as influx or eﬄux transporters has been reported
in the CNS. Indeed, rat cortical neurons when cultured
alone are able to release adenosine after N-methyl-D-aspartate
(NMDA) stimulation, whereas the NMDA-triggered increase
in extracellular adenosine concentration appears to be related
to nucleotide degradation when neurons are co-cultured with
astrocytes (Zamzow et al., 2008). In rat hippocampal slices
it has been shown that ATP is able to promote adenosine
release via ENT-type proteins, which in turn might activate A2A
receptors (Almeida et al., 2003). Subsequently, A2A activation
might promote adenosine uptake, as shown in hippocampal
synaptosomes (Pinto-Duarte et al., 2005). In fact, adenosine
uptake via ENT-type transporters appears to reduce extracellular
adenosine levels in hypoxia which suggests that ENT proteins
and probably ENT1 in particular might be suitable targets for the
treatment of cerebral ischemia (Zhang et al., 2011). Interestingly,
adenosine in the brain has also been related to addictive
behaviors, among them alcohol addiction. It has been known
for a long time that ethanol increases extracellular adenosine
by inhibiting in a somehow selective manner ENT1 function
(Nagy et al., 1990). Nevertheless the most conclusive evidence
supporting this pharmacological effect comes from functional
genomics. The ENT1 knock out mouse model shows reduced
acute responses to ethanol intake and increased addiction to
alcohol (Choi et al., 2004). This animal model has also been useful
in the understanding of ENT1-related adenosine signaling in
other organs. In fact, ENT1-null mice show increased adenosine
plasma levels and are cardioprotected (Rose et al., 2010,
2011). Similarly, ENT1 appears to be implicated in adenosine-
related protection in the liver during ischemia and reperfusion
(Zimmerman et al., 2013).
Moreover, adenosine contributes to chronic kidney disease,
particularly in diabetes. Increased adenosine signaling via
A2B receptors has been reported to be involved in diabetic
glomerulopathy (Cárdenas et al., 2013), and increased adenosine
levels in insulin-deficient states have been associated with down-
regulation of ENT2 transport function in podocytes (Alarcón
et al., 2017). In a complementary manner, in proximal tubule
cells, decreased ENT1 function has also been related to fibrosis in
diabetic nephropathy (Kretschmar et al., 2016). In fact, ENT1 null
mouse shows a spontaneous tendency to develop renal fibrosis
whereas ENT1 silencing in human kidney epithelial (HK) cells
results in the promotion of epithelial-to-mesenchymal transition
(EMT) (Guillén-Gómez et al., 2012). Promotion of EMT in
HK2 cells can be mimicked by TFG-β1, whereas adenosine itself
mediates TFG-β1 release from glomeruli of diabetic rats via A2B
receptor activation (Roa et al., 2009).
The involvement of ENT proteins in the regulation
of adenosine tone in vascular endothelium has been
comprehensively studied using Human Umbilical Vein
Endothelial Cells (HUVECs) and Placenta Microvascular
Endothelial Cells (PMECs) as experimental models (review in
Sobrevia et al., 2011; Pardo et al., 2013). As in other cell types,
it has been shown that control of extracellular adenosine levels
via P1 receptors also involves hENT modulation, in particular
the hENT1 and hENT2 subtypes (Escudero et al., 2008; Pardo
et al., 2013). In some cases, opposite effects on each transporter
protein have been reported, thereby suggesting either some sort
of physiological compensation or an hENT-subtype specific
effect impacting on the ability of removing from the extracellular
milieu not only adenosine but also some of its catabolites. hENT2
is indeed a suitable hypoxanthine transporter. Interestingly, we
have recently shown that hENT1 and hENT2 can form oligomers
hENT1-hENT1, hENT2-hENT2, but also hENT1-hENT2, with
multiple functional consequences (Grañé-Boladeras et al., 2002).
Overall, it is within this framework that the pharmacological
use of ENT inhibitors such as dipyridamole and dilazep can be
understood (Figueredo et al., 1999). Nevertheless, at least for
cardioprotection, it has recently been argued that ENT4 could
become a better target than ENT1, because of the more restricted
tissue expression pattern of the former ENT subtype (Yang and
Leung, 2015). As discussed above, ENT4 was shown to be a
suitable cardiac adenosine transporter at acidic pH (Barnes et al.,
2006). Then, the idea these authors discuss is that most cell types
may rely upon ENT1 for nucleoside salvage purposes, thereby
making any ENT1-targeting drug more likely to present adverse
effects than newly developed molecules targeting ENT4.
CNT Proteins
As discussed above, hCNT2 and hCNT3 should be, by far,
the best candidates for efficient removal of adenosine from
the extracellular milieu. This statement is based upon their
apparent high affinity for adenosine and for its concentrative
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capacity which is even 10 fold higher for hCNT3 than hCNT2.
Nevertheless, hCNT pharmacology is very poor, even though
some hCNT subtype specific inhibitors have been recently
proposed (Kumar Deokar et al., 2017). In this regard the
structural modeling of human CNT subtypes (Arimany-Nardi
et al., 2017; Kumar Deokar et al., 2017; Latek, 2017; Mulinta et al.,
2017) based upon the crystal structure of the Vibrio cholerae CNT
ortholog (Johnson et al., 2012) might be particularly useful for
future specific inhibitor design. This has been a major bottleneck
to study the probable impact of acute CNT pharmacological
inhibition on adenosine signaling. Nevertheless there is solid
experimental evidence showing that CNT2 and CNT3 are under
purinergic regulation, which suggests they contribute, as ENTs, to
modulate extracellular adenosine levels and P1 signaling.
In liver parenchymal cells CNT2 is expressed at the basolateral
(sinusoidal) and apical (canalicular) plasma membranes (Duflot
et al., 2002; Govindarajan et al., 2008). In rat primary hepatocytes
and hepatocarcinoma FAO cells the activity of this transporter
protein is under purinergic regulation via A1 receptors (Duflot
et al., 2004). This effect is relatively rapid (peaking between
5 and 10 min after agonist addition) and consistent with
increased transport capacity (Vmax effect). Interestingly the
magnitude of the effect (transport fold-induction) is dependent
upon glucose concentration, being lower at high glucose (10 vs.
5 mM glucose). Indeed, CNT2 up-regulation could be blocked
by inhibitors of KATP channels and mimicked by openers,
which establishes a putative link between energy metabolism
and purinergic regulation of CNT2. All the protein machinery
likely to be implicated in this phenomenon, this is the KATP
channel subunits Kir6.1, Kir6.2, SUR2A, SUR2B, as well as the
transporter itself and A1 receptors were shown to co-localize in
FAO cells. The physiological impact of the reduction of adenosine
removal capacity triggered by high-glucose is not clear, although
decreased hENT1 function and expression have been reported
in HUVEC from diabetic patients and shown to be mimicked
by high glucose in the culture medium (Sobrevia et al., 2011).
It is interesting to keep in mind that extracellular adenosine has
been reported to be able to modulate the AMP-dependent kinase
AMPK, by a mechanism which depends on transporter function,
also involving CNT2 in some cell types (Aymerich et al., 2006).
Overall, CNT2 appears to be a suitable candidate to modulate
purinergic signaling in hepatocytes, particularly considering that
hCNT1 is not an adenosine transporter and hCNT3 expression
in hepatocytes appears to be negligible. Interestingly, CNT2
function has recently been identified in primary rat bile duct
epithelial cells where it is similarly found in both plasma
membrane domains, apical and basolateral of cholangiocytes
(Godoy et al., 2014). Luminal ATP, via P2Y receptors, down-
regulates apical (lumen-facing) CNT2 activity by a Ca++-
dependent mechanism. Cholangiocytes also express CNT3 and
its apical function is similarly down-regulated by nucleotides,
such as ATP. However, A2A agonists (i.e., adenosine), acting
from the luminal side, specifically activate apical CNT3, without
modifying CNT2 function. CNT3 activation is consistent with
transporter trafficking from intracellular vesicles to the plasma
membrane. In practice this means that CNT2 and probably to
more extent CNT3 are contributing to end up the purinergic
regulation of bile flow by removing adenosine from the bile
canaliculus. It makes sense that the adenosine precursor ATP
reduces adenosine removal capacity by inhibiting both CNT2 and
CNT3, whereas the differential regulation of both transporters
by adenosine acting on A2A receptors may reflect basal (CNT2
and CNT3) and adenosine-induced (CNT3) capacity for its own
removal.
CNT2, in parallel with ENT1, has also been mapped in the
adult rat brain by in situ hybridization (Guillén-Gómez et al.,
2004). Indeed, CNT2 is broadly distributed in the CNS with
significant overlapping with ENT1. More recently, others have
identified the CNT2 protein in plasma and vesicle membranes
isolated from rat striatum (Melani et al., 2012). The possibility
of CNT2 also playing a role in adenosine signaling in the brain
is also supported by the evidence that its activity can be up-
regulated by P1 receptor activation in differentiated neural PC12
cells (most probably A1 and A2A) (Medina-Pulido et al., 2013).
CNT2 activation is relatively rapid, as in hepatocytes, peaking
15 min after P1 agonist addition. Interestingly, caffeine has been
reported to inhibit CNT2 function with an apparent Ki value of
103 µM (Lang et al., 2004). Although this concentration might
significantly exceed the one found in blood after coffee ingestion,
it could still be relevant in heavy coffee drinkers (Nehlig and
Debry, 1994). Taking together these observations suggest ENT1
may not be the only player regulating adenosine signaling in
the brain, which in fact is consistent with the relatively mild
phenotype of the ENT1 null mice.
Last, but not least, several physiological and
pathophysiological observations also support a role for hCNT2
and hCNT3 as proteins relevant to purinergic signaling. The
three hCNT genes are expressed in the nephron and accurate
anatomic analysis of their distribution along it reveals a
longitudinal pattern of expression consistent with nucleoside
renal tubule reabsorption but also with adenosine-mediated
tubulo-glomerular feedback regulation (Schnermann, 2015).
Indeed, the three transporter proteins are expressed in the
proximal convoluted tubule (PCT), where most nutrient
reabsorption (glucose, amino acids) take place, but only the two
adenosine transporters (CNT2 and CNT3), not CNT1, are also
expressed in very specific distal segments of the nephron, the
cortical collecting duct (CCD) (CNT3) and the outer medullary
collecting duct (OMCD) (CNT2). This anatomical distribution
is more consistent with adenosine signaling than with nucleoside
reabsorption. Distribution of CNTs along the gastrointestinal
tract (Pastor-Anglada et al., 2018) also points to this dual
role of adenosine transporters. In fact, the CNT2 encoding
gene (SLC28A2) is, by far, the one which is down-regulated
the most (sevenfold) in inflamed ileon mucosa from Crohn’s
patients (Pérez-Torras et al., 2016). Even though the impact
of inflammation is broad and down-regulates a broad cohort
of genes, those associated with the purinome (transporters,
receptors, and ectonucleotidases) are greatly affected.
In the rat brain, CNT2 is also down-regulated in situations
known to be associated with increased adenosine concentrations.
CNT2 mRNA levels are decreased in cortical samples from
sleep-deprived rats, whereas ENT1 mRNA is not affected at
all under the same circumstances (Guillén-Gómez et al., 2004).
Frontiers in Pharmacology | www.frontiersin.org 6 June 2018 | Volume 9 | Article 627
fphar-09-00627 June 12, 2018 Time: 17:56 # 7
Pastor-Anglada and Pérez-Torras Adenosine Transporters
CNT2-related mRNA tends to recover when animals are allowed
to sleep. On the other hand, experimental ischemia in vivo,
induced in rats by intraluminal middle cerebral arterial occlusion,
also regulates nucleoside transporter encoding genes (Medina-
Pulido et al., 2013). In this study, transcripts of both ENTs (ENT1
and ENT2) and the three CNT members were quantified in the
ipsilateral cortex (infarcted) and compared to the contralateral
cortex as its own control. Indeed, the mRNA levels of hENT1,
hCNT2, but also hCNT3 (poorly studied in the brain), the
three transporters more likely to modulate adenosine tone, were
decreased in the infarcted tissue with no changes observed for
hCNT1 and hENT2.
CONCLUDING REMARKS AND FUTURE
PERSPECTIVES
Nucleoside transport by each particular nucleoside protein
subtype cannot be measured directly, thereby resulting in some
experimental variability likely to impact on the determination
of adenosine affinity constants. Despite this limitation, we can
conclude that adenosine transport mechanisms across the plasma
membrane are well-understood with the only exception of ENT4,
for which a clear role in the regulation of adenosine tone in
some tissues (i.e., heart) still awaits clarification. Nevertheless,
in general trends, who is who in adenosine transport is well-
known.
Less clear is how each transporter subtype contributes
to modulate adenosine levels, an issue of particular interest
considering most cells show some apparent redundancy in
the expression of adenosine transporters. ENT1 is by far the
most studied adenosine transporter. This may be explained,
as discussed above, not necessarily because of its ubiquitous
expression, but because pharmacological tools and functional
genomics have provided better chances to study it than for the
other adenosine transporters. Nevertheless, the contribution of
the other subtypes, particularly CNTs (CNT2 and CNT3) should
not be ruled out and deserves further investigation.
Although CNT and ENT subtype expression appears to be
polarized in (re)absorptive epithelia, thus allowing vectorial flux
of substrates, in other epithelial cell types CNT and ENT proteins
appear to be located in both poles (apical and basolateral), thereby
anticipating other roles beyond absorption (Pastor-Anglada et al.,
2018). Moreover, non-epithelial cells, such as adipocytes (Guallar
et al., 2007) and immune system cells (Soler et al., 1998, 2001;
Minuesa et al., 2009, 2011) also express ENT and CNT proteins.
Whether particular subtypes are under purinergic regulation in
these cells and tissues has not been properly addressed until now.
Last, but not least, there is also the possibility of local regulation
of selected adenosine transporters even at the single cell level,
thereby providing some sort of compartmental regulation of
biological functions. In this regard, ENT and CNT protein
interactomics might help to unveil novel regulatory events likely
to facilitate the fine tuning of purinergic regulation.
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